HealthTech Build is hosting a unique discussion about changes in the MedTech landscape with leaders from Boston Scientific, Medtronic, and more. Join us for this free event!
When: Wednesday, April 10th, 6:000 – 8:00PM
Where: WPI Seaport, 303 Congress Street, Boston
Join representatives from leading MedTech companies to understand the role technology is playing in the next generation of medical devices. The discussion will cover emerging trends in business and science as medical devices and digital technology converge.
This event is intended for entrepreneurs and leaders from MedTech businesses who want to navigate the business and regulatory complexities of the MedTech space. This event will also be of interest to developers, medical researchers, clinicians, data scientists, and more.
David Feygin, PhD, MBA
As Chief Digital Health Officer, David leads Boston Scientific’s Digital Health strategy and chairs the cross-functional Digital Health Council. David is responsible for leading the core Big Data, Internet of Things (IoT), Analytics and Mobility teams, and partnering to establish the evolving capabilities that will ensure enterprise success in Digital Health. Previously, as VP of Health IT Integration and Strategic Innovation at Becton Dickinson (BD), David led the company’s enterprise-wide health information technology capability development efforts to ensure commercial success and developed actionable strategies to improve patient outcomes, drive health system efficiency and enable BD’s growth through the application of information technology. David is Chair of the Executive Council for The Center for Patient Safety Research and Practice, a thought leader in information-enabled healthcare safety with a primary focus on medication error and patient safety research.
Geoff is currently a Director of Business Development and Licensing within the Surgical Innovations business of Medtronic, where he coordinates M&A and other strategic partnership activities. Geoff joined Medtronic in 2015 following its acquisition of Covidien PLC. He started with Covidien in 2008, serving in various roles, including Director of Strategy and Business Development within the Vascular Therapies business. Previously, he worked in the Transaction Advisory Services group of Ernst & Young, as well as multiple Boston boutique advisory firms.
Kristine is the Vice President of Regulatory at Analytics 4 Life, a digital health company using artificial intelligence to develop predictive algorithms and medical imaging solutions. Previously she held senior management roles in regulatory and quality where she developed product approval strategies and managed execution of product clinical and commercial regulatory applications for the U.S., Europe, and Canada. Kristine has supported medical device products across a variety of therapeutic areas, such as cardiology, endovascular surgery, breast surgery, wound care, soft tissue repair, dental, orthopedics, and neurosurgery.
Dr. Ellen Baron
Ellen is the Managing Director at Outcome Capital, bringing extensive experience in the private placement of securities for life science companies with deep domain expertise across multiple disciplines in pharmaceutical and biotechnology industries. She has been involved in the raise of more than $150M of investment capital and has $2B in deals to her credit from her days in pharma and biotech. Dr. Baron currently serves on the Board of Directors of Tetragenetics Inc., a Boston-based biotech pioneering antibodies to ion channels, Sixth Element Capital, a UK-based oncology focused venture capital fund and SFH, a Maine-based nutraceutical company. Dr. Baron was most recently a Managing Director at Healthios Capital Markets, LLC, leading their firm’s biopharmaceutical practice. Prior to that she spent 9 years as Partner at Oxford Bioscience Partners, a Boston-based life science venture capital firm where she led numerous therapeutic and diagnostic investments within the $1 billion portfolio of 149 companies.
Doors open at 6:00PM and the discussion and Q&A will run from 6:30-7:30PM. Light refreshments will be provided.